Chandra, Amitabh →

Can a ‘Basic Bundle’ of Health Insurance Cure Coverage Gaps and Spur Innovation?

One in 10 people in America lack health insurance, resulting in $40 billion of care that goes unpaid each year. Amitabh Chandra and colleagues say ensuring basic coverage for all residents, as other wealthy nations do, could address the most acute needs and unlock efficiency.

The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation

Expediting so-called breakthrough therapies has saved millions of dollars in research time without compromising drug safety or efficacy, says research by Ariel Stern, Amitabh Chandra, and colleagues. Could policymakers harness the approach to bring life-saving treatments to the market faster?

Can Amazon Remake Health Care?

Amazon has disrupted everything from grocery shopping to cloud computing, but can it transform health care with its One Medical acquisition? Amitabh Chandra discusses company's track record in health care and the challenges it might face.

A Rare Find in Health Care: A Simple Solution to Racial Inequity

Research by Amitabh Chandra offers a stark new explanation for racial disparities in heart attack survival rates—a problem with immediate answers. Open for comment; 0 Comments.

The Health Costs of Cost-Sharing

Small increases in cost cause patients to reduce their use of drugs with major benefits, ultimately causing their death. Since patient cost-sharing introduces large and deadly distortions into the cost-benefit calculus, payers should evaluate the merits of policies in light of their impact on health, not just on health care costs.

Hospital Allocation and Racial Disparities in Health Care

Black Americans experience disparities in health outcomes in the United States relative to other demographic groups. This study of heart attack sufferers over two decades develops a framework to examine the allocation of health care and the effectiveness of medical treatments, including beta-blockers and other technologies.

What Can Economics Say About Alzheimer's Disease?

This essay discusses the role of market frictions and "missing medicines" in drug innovation and highlights how frameworks and toolkits of economists can help our understanding of the determinants and effects of Alzheimer's disease on health.

Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.

Retail pharmacy data illustrates it can be misleading to use list prices instead of net prices to understand pharmaceutical prices. Analysts and economists working in public policy should be extremely cautious in drawing policy conclusions based on list prices alone.

Post-COVID Health Care: More Screens, Less Red Tape?

The coronavirus pandemic might lead to major changes in patient care, physician compensation, and regulation. Experts from Harvard Business School's Health Care Initiative share their predictions. Open for comment; 0 Comments.

Identifying Sources of Inefficiency in Health Care

This economic study finds evidence of allocative inefficiency and substantial variation in comparative advantage across hospitals, with the benefits from treatment being much higher in some hospitals than others. The study overall suggests new directions for research on productivity in healthcare.